Sermorelin- 10mg - Research Peptide

Description

Description

Product Name: Sermorelin
Also Known As: Sermorelin Acetate, GHRH (1–29)
Molecular Weight: Approximately 3,357 g/mol 
Form: Lyophilized Powder
Quantity: 10 mg
Purity: ≥ 98% (HPLC Verified)

Product Overview:

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It retains the biological activity of GHRH and has been studied for its ability to stimulate the release of endogenous growth hormone (GH) from the anterior pituitary gland.

Unlike human growth hormone (HGH), Sermorelin does not directly supply growth hormone. Instead, it interacts with GHRH receptors in the pituitary gland, stimulating the body's own growth hormone release. This process produces a pulsatile release pattern that remains subject to normal physiological feedback mechanisms.

Controlled human physiology studies have demonstrated that GHRH (1–29) can increase circulating growth hormone concentrations in healthy volunteers. However, the magnitude of this response varies depending on age, pituitary function, endocrine status, and experimental conditions.

An observed increase in growth hormone does not necessarily establish a specific clinical benefit.

Applications in Research:

• Sermorelin has been investigated in several areas of endocrine and physiological research, including:

  • Growth Hormone Regulation: Studies examining stimulation of endogenous growth hormone secretion.

  • Pituitary Function: Investigations into hypothalamic-pituitary signaling and pituitary responsiveness.

  • Endocrine Research: Studies evaluating growth hormone and insulin-like growth factor 1 (IGF-1) levels.

  • Age-Related Endocrine Changes: Research examining differences in growth hormone secretion across age groups.

  • Body Composition Research: Investigations exploring growth hormone pathways, lean body mass, and metabolic outcomes.

  • Pediatric Growth Research: Historical research involving children with diagnosed growth hormone deficiency.

Research Evidence & Limitations

Published research involving Sermorelin and related GHRH compounds varies considerably by population, study design, and measured outcomes.

Important distinctions include:

Pediatric Growth Hormone Deficiency: Historical clinical evidence is most directly associated with children diagnosed with growth hormone deficiency. Research involved weight-based protocols and medically supervised populations.

Healthy Adults and Older Adults: Studies involving GHRH and related compounds have demonstrated endocrine responses, including changes in growth hormone and IGF-1. However, improvements in body composition and other clinical outcomes have not been consistently demonstrated.

Performance and Body Composition: Although growth hormone secretagogues have attracted research interest in muscle development, fat metabolism, and physical performance, available clinical evidence remains limited. Search popularity and mechanistic findings should not be interpreted as proof of therapeutic effectiveness.

Current FDA materials do not establish an approved adult growth-hormone-deficiency dosing regimen for Sermorelin.

Research Considerations & Safety

Historical clinical literature has reported potential adverse effects associated with Sermorelin, including:

• Transient facial flushing

• Injection-site discomfort or pain

• Localized swelling at the administration site

Research involving the growth hormone axis also warrants consideration of endocrine and metabolic effects. Observed effects can vary according to the compound, exposure, and study population.

These findings should not be interpreted as a complete safety profile or as evidence of safety for unapproved uses.

Storage & Handling:

Store lyophilized powder at -20°C in a dark, moisture-controlled environment.
Reconstitute using bacteriostatic water under sterile lab conditions. Use reconstituted solution within standard research timelines and refrigerate at 2–8°C. Do not refreeze.

⚠️ Research Use Only – Legal Disclaimer

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.

Biogenic Foods, LLC is a chemical supplier. Biogenic Foods is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Biogenic Foods is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption.